{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:37:50Z","timestamp":1787769470410,"version":"build-2784847793"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To evaluate the safety and efficacy of stereotactic body radiation therapy (SBRT) for 70 years or older patients with advanced hepatocellular carcinoma (aHCC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>This observational retrospective study was done between May 2020 and March 2023. The data of 24 elderly patients with aHCC treated with SBRT were collected from the hospital electronic records. Patients with Child-Turcotte-Pugh status (CTP) A5 to B8 and a functional liver reserve of \u2265700cc were included. Local control, overall survival (OS), progression-free survival (PFS), and postprocedure adverse events were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The median follow-up period of the study cohort was 13 months (range: 3\u201336 months). The median age was 75 years (range: 70\u201384 years) with CTP A (70.8%) and CTP B (29.2%). NASH was the most common etiology (n = 15, 62.5%). The median tumor diameter was 8.5 cm (range, 5\u201316). Portal vein and IVC tumor thrombosis were seen in 21 (87.5%) and 4 (16.67%) patients. The median SBRT dose to gross tumor of 35 Gy (range 25\u201340 Gy) is delivered in five fractions. Though the median AFP level was reduced from 136.5 (range 3.7\u201327533) to 34.5 (range 3\u20134964) ng\/ml, the difference was not significant. The median PIVKA II level was significantly decreased from 2702 (range 23.8\u2013385454) to 189 (range 15\u201356262) mAU\/ml,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.05. The estimated local control rates at 12 and 18 months were 90% and 62%, respectively. The 1-year estimated OS and PFS rates were 58% and 42%, respectively. The mOS and mPFS were 14 months (95% CI, 8.5\u201319.4) and 9 months (95% CI, 5.5\u201312.4), respectively. On multivariate analysis, baseline geriatric 8 (G8) score \u22649 and CTP B were the predictors of poor OS. SBRT was found to be generally safe in patients with geriatric 8 score &gt;9 with postprocedure decompensation (increased CTP score by 2 points) in only one (4.16%) patient.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>SBRT is a safe and effective locoregional therapy in elderly subjects with cirrhosis and locally advanced HCC. In elderly patients, with limited transplant and other therapeutic options, SBRT is safe and provides improved local disease control, OS, and PFS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_1118_24","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T16:42:46Z","timestamp":1743698566000},"page":"137-144","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of stereotactic body radiation therapy in elderly patients with cirrhosis and large advanced hepatocellular carcinoma"],"prefix":"10.4103","volume":"21","author":[{"given":"Deepti","family":"Sharma","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Institute of Liver and Biliary Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babu Lal","family":"Meena","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. V","family":"Anju","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institute of Liver and Biliary Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Jagya","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institute of Liver and Biliary Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiv Kumar","family":"Sarin","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanuman Prasad","family":"Yadav","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institute of Liver and Biliary Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"R1-20250403","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020:An overview","author":"Ferlay","year":"2021","journal-title":"Int J Cancer"},{"key":"R2-20250403","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"GlobalCancer Statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R3-20250403","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1634\/theoncologist.5-3-224","article-title":"Management of cancer in the older person:A practical approach","volume":"5","author":"Balducci","year":"2000","journal-title":"Oncologist"},{"key":"R4-20250403","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1200\/JCO.2002.20.2.494","article-title":"Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients:An Italian Group for Geriatric Oncology Study","volume":"20","author":"Repetto","year":"2002","journal-title":"J Clin Oncol"},{"key":"R5-20250403","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.3892\/ol.2013.1566","article-title":"Age is a prognostic factor affecting survival in lung cancer patients","volume":"6","author":"Tas","year":"2013","journal-title":"Oncol Lett"},{"key":"R6-20250403","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1053\/j.gastro.2008.02.090","article-title":"Diagnosis and treatment of hepatocellular carcinoma","volume":"134","author":"El-Serag","year":"2008","journal-title":"Gastroenterology"},{"key":"R7-20250403","doi-asserted-by":"crossref","first-page":"101269","DOI":"10.1016\/j.jceh.2023.08.005","article-title":"2023 Update of Indian National Association for study of the liver consensus on management of intermediate and advanced hepatocellular carcinoma:The Puri III recommendations","volume":"14","author":"Kumar","year":"2023","journal-title":"J Clin Exp Hepatol"},{"key":"R8-20250403","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.prro.2021.09.004","article-title":"External beam radiation therapy for primary liver cancers:An ASTRO clinical practice guideline","volume":"12","author":"Apisarnthanarax","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"R9-20250403","doi-asserted-by":"crossref","first-page":"102386","DOI":"10.1016\/j.jceh.2024.102386","article-title":"Exploring the evolving landscape of stereotactic body radiation therapy in hepatocellular carcinoma","volume":"15","author":"Sharma","year":"2025","journal-title":"J Clin Exp Hepatol"},{"key":"R10-20250403","author":"Dawson","journal-title":"Radiation Therapy Oncology Group (RTOG) 1112 randomized phase III study of sorafenib versus stereotactic body radiation therapy followed by sorafenib in hepatocellular carcinoma 2012"},{"key":"R11-20250403","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.jgo.2021.01.001","article-title":"Charlson comorbidity index and G8 in older old adult (\u226580 years) hepatocellular carcinoma patients treated with stereotactic body radiotherapy","volume":"12","author":"Loi","year":"2021","journal-title":"J Geriatr Oncol"},{"key":"R12-20250403","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/hepr.12916","article-title":"Clinical outcomes of stereotactic body radiotherapy for elderly patients with hepatocellular carcinoma","volume":"48","author":"Teraoka","year":"2018","journal-title":"Hepatol Res"},{"key":"R13-20250403","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s00066-023-02065-x","article-title":"Role of palliative SBRT in barcelona clinic liver cancer-stage C hepatocellular carcinoma patients","volume":"199","author":"Sharma","year":"2023","journal-title":"Strahlenther Onkol"},{"key":"R15-20250403","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"R16-20250403","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/1476-4598-9-146","article-title":"Integrative and comparative genomics analysis of early hepatocellular carcinoma differentiated from liver regeneration in young and old","volume":"9","author":"Colak","year":"2010","journal-title":"Mol Cancer"},{"key":"R17-20250403","doi-asserted-by":"crossref","first-page":"136","DOI":"10.17998\/jlc.2022.08.18","article-title":"Stereotactic body radiation therapy for elderly patients with small hepatocellular carcinoma:A retrospective observational study","volume":"22","author":"Jang","year":"2022","journal-title":"J Liver Cancer"},{"key":"R18-20250403","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jgo.2020.03.018","article-title":"The efficacy and safety of sorafenib in older adults with advanced hepatocellular carcinoma:An analysis of a majority Hispanic cohort","volume":"11","author":"Arora","year":"2020","journal-title":"J Geriatr Oncol"},{"key":"R19-20250403","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.ijrobp.2018.04.011","article-title":"Baseline albumin-bilirubin (ALBI) score in western patients with hepatocellular carcinoma treated with stereotactic body radiation therapy (SBRT)","volume":"101","author":"Murray","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R20-20250403","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/1754-9485.13527","article-title":"Role of stereotactic body radiotherapy for inferior vena cava tumour thrombus in hepatocellular carcinoma","volume":"67","author":"Sharma","year":"2023","journal-title":"J Med Imaging Radiat Oncol"},{"key":"R21-20250403","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000521374","article-title":"Newly developed modified ALBI grade shows better prognostic and predictive value for hepatocellular carcinoma","volume":"11","author":"Kudo","year":"2022","journal-title":"Liver Cancer"},{"key":"R22-20250403","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.3390\/jcm11144183","article-title":"Inflammatory indexes as prognostic factors of survival in geriatric patients with hepatocellular carcinoma:A case control study of eight slovak centers","volume":"11","author":"Safcak","year":"2022","journal-title":"J Clin Med"},{"key":"R23-20250403","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jhep.2013.05.025","article-title":"Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma","volume":"59","author":"Golfieri","year":"2013","journal-title":"J Hepatol"},{"key":"R24-20250403","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation:The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"R25-20250403","doi-asserted-by":"crossref","first-page":"e2498","DOI":"10.6061\/clinics\/2021\/e2498","article-title":"Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma","volume":"76","author":"Marta","year":"2021","journal-title":"Clinics (Sao Paulo)"},{"key":"R26-20250403","doi-asserted-by":"crossref","first-page":"100991","DOI":"10.1016\/j.jhepr.2023.100991","article-title":"Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion:A phase 2 study","volume":"6","author":"Kim","year":"2023","journal-title":"JHEP Rep"},{"key":"R27-20250403","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150:Atezolizumab plus bevacizumab vs. Sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1118_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:59:57Z","timestamp":1786647597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1118_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1118_24","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-06-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}